Novo Plans Phase III Program To Pick Up Obesity Claim For Victoza
This article was originally published in The Pink Sheet Daily
Executive Summary
Novo Nordisk is moving ahead with plans to develop Victoza (liraglutide) for obesity now that U.S. regulators are comfortable with the GLP-1's risk/benefit profile.
You may also be interested in...
Novo Is On Track To File Liraglutide For Obesity By 2014
Novo Nordisk reported positive data from a Phase III trial of liraglutide in sleep apnea, completing the drug’s clinical program in obesity. It expects to file for regulatory approval of the drug as a weight reducer by year end.
Once-Weekly Insulin Added To Novo Nordisk’s Clinical Pipeline
Novo Nordisk is evaluating new long-acting and quick-acting insulins in clinical trials as competitive pressure looks set to intensify in 2013 for its market-leading GLP-1 agonist, Victoza.
Obesity Drug Developers Go With The Gut: R&D Hopes Focus On Locally Acting Agents
Developers remaining in the daunting weight loss space are pinning their hopes on a new wave of locally acting drugs with the hope that gut-selective mechanisms will show better efficacy combined with fewer safety concerns than the three centrally acting obesity candidates recently rebuffed by FDA.